🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

Recruitingn/aAges 1 Day - 24 MonthsAllFederico Martinón Torres
NCT06180993 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Subjects born in Galicia from April 1st, 2023 and March 1st, 2026 Exclusion Criteria: * No specific criteria has been reported
💊

What it tests

  • Nirsevimab
📍

Where

1 site
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy